<DOC>
	<DOCNO>NCT02446730</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety 5mg maintenance dose ( MD ) prasugrel patient acute myocardial infarction ( AMI ) undergo percutaneous coronary intervention ( PCI ) BiomatrixTM stent .</brief_summary>
	<brief_title>Efficacy Safety BiomatrixTM Stent 5mg-Maintenance Dose Prasugrel Patients With Acute Coronary Syndrome</brief_title>
	<detailed_description>About 1400 patient derived Korean patient acute coronary syndrome ( ACS ) receive percutaneous coronary intervention ( PCI ) BES ( Biolimus-eluting stent , BiomatrixTM ) routine manner enrol investigator trial . These patient randomize 1:1 either prasugrel 5mg daily MD clopidogrel 75mg daily MD successful PCI BES . The investigator exclude patient age ≥75 year , body weight &lt; 60 kg , history TIA ( transient ischemic attack ) stroke . Follow-up data collect 1-year index procedure . Primary efficacy end-point define composite cardiac death , non-fatal MI , stent thrombosis ischemic driven target vessel revascularization safety end-points BARC ( Bleeding Academic Research Consortium ) type ≥ 2 bleeding .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Death</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<criteria>Patients undergo percutaneous coronary intervention Biomatrix stent history TIA stroke , 75 year old young , body weight 60 kg diagnose acute coronary syndrome Patients history TIA stroke , 75 year old old , body weight 60 kg , hypersensitivity contraindicate heparin , aspirin , clopidogrel , prasugrel contrast medium</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>